NCT03360747View on ClinicalTrials.gov

Phase 2 Study of AKCEA-ANGPTL3-LRx (ISIS 703802) in Participants With Familial Chylomicronemia Syndrome (FCS)

PHASE2CompletedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

December 21, 2017

Primary Completion Date

June 12, 2018

Study Completion Date

September 4, 2018

Conditions
Familial Chylomicronemia SyndromeLipoprotein Lipase DeficiencyHyperlipoproteinemia Type 1
Interventions
DRUG

AKCEA-ANGPTL3-LRx

AKCEA-ANGPTL3-LRx at dose 20 mg, administered via SC injection QW.

Trial Locations (1)

H2W 1R7

Investigative Site, Montreal

Sponsors

Lead Sponsor

Akcea Therapeutics
All Listed Sponsors
collaborator

Ionis Pharmaceuticals, Inc.

INDUSTRY

lead

Akcea Therapeutics

INDUSTRY